122 related articles for article (PubMed ID: 14741282)
21. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia.
Ballinger JR; Kee JW; Rauth AM
J Nucl Med; 1996 Jun; 37(6):1023-31. PubMed ID: 8683295
[TBL] [Abstract][Full Text] [Related]
22. Modulation of in vivo distribution through chelator: Synthesis and evaluation of a 2-nitroimidazole-dipicolylamine-(99m)Tc(CO)3 complex for detecting tumor hypoxia.
Mallia MB; Mittal S; Sarma HD; Banerjee S
Bioorg Med Chem Lett; 2016 Jan; 26(1):46-50. PubMed ID: 26615889
[TBL] [Abstract][Full Text] [Related]
23. Kit formulation for preparation and biological evaluation of a novel (99m)Tc-oxo complex with metronidazole xanthate for imaging tumor hypoxia.
Li Z; Lin X; Zhang J; Wang X; Jin Z; Zhang W; Zhang Y
Nucl Med Biol; 2016 Feb; 43(2):165-70. PubMed ID: 26872441
[TBL] [Abstract][Full Text] [Related]
24. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia.
Ng CK; Sinusas AJ; Zaret BL; Soufer R
Circulation; 1995 Sep; 92(5):1261-8. PubMed ID: 7648674
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and preliminary biological evaluation of the 99mTc labeled nitrobenzoimidazole and nitrotriazole as tumor hypoxia markers.
Zhang Y; Chu T; Gao X; Liu X; Yang Z; Guo Z; Wang X
Bioorg Med Chem Lett; 2006 Apr; 16(7):1831-3. PubMed ID: 16460938
[TBL] [Abstract][Full Text] [Related]
26. Nitroimidazoles and hypoxia imaging: synthesis of three technetium-99m complexes bearing a nitroimidazole group: biological results.
Riché F; d'Hardemare AD; Sèpe S; Riou L; Fagret D; Vidal M
Bioorg Med Chem Lett; 2001 Jan; 11(1):71-4. PubMed ID: 11140737
[TBL] [Abstract][Full Text] [Related]
27. In vivo click reaction between Tc-99m-labeled azadibenzocyclooctyne-MAMA and 2-nitroimidazole-azide for tumor hypoxia targeting.
Sun W; Chu T
Bioorg Med Chem Lett; 2015 Oct; 25(20):4453-6. PubMed ID: 26358160
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and evaluation of two technetium-99m-labeled peptidic 2-nitroimidazoles for imaging hypoxia.
Su ZF; Zhang X; Ballinger JR; Rauth AM; Pollak A; Thornback JR
Bioconjug Chem; 1999; 10(5):897-904. PubMed ID: 10502359
[TBL] [Abstract][Full Text] [Related]
29. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia.
Engelhardt EL; Schneider RF; Seeholzer SH; Stobbe CC; Chapman JD
J Nucl Med; 2002 Jun; 43(6):837-50. PubMed ID: 12050331
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological characterisation of novel dithiocarbamate containing 5-nitroimidazole (99m)Tc-complexes as potential agents for targeting hypoxia.
Giglio J; Fernández S; Rey A; Cerecetto H
Bioorg Med Chem Lett; 2011 Jan; 21(1):394-7. PubMed ID: 21087863
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, radiolabeling and biological evaluation of propylene amine oxime complexes containing nitrotriazoles as hypoxia markers.
Huang H; Mei L; Chu T
Molecules; 2012 Jun; 17(6):6808-20. PubMed ID: 22664468
[TBL] [Abstract][Full Text] [Related]
32. A Novel Tumor Hypoxia Imaging Agent: [
Lin X; Tan X; Wu F; Yu Q
Curr Radiopharm; 2023; 16(4):300-307. PubMed ID: 36959152
[TBL] [Abstract][Full Text] [Related]
33. A novel amine-dioxime chelator for technetium-99m: synthesis and evaluation of 2-nitroimidazole-containing analogues as markers for hypoxic cells.
Su ZF; Ballinger JR; Rauth AM; Abrams DN; Billinghurst MW
Bioconjug Chem; 2000; 11(5):652-63. PubMed ID: 10995208
[TBL] [Abstract][Full Text] [Related]
34. [99mTc]Technetium labelled PnAo-azomycin glucuronides: a novel class of imaging markers of tissue hypoxia.
Kumar P; Wiebe LI; Mannan RH; Zhang Z; Xia H; McEwan AJ
Appl Radiat Isot; 2002 Nov; 57(5):719-28. PubMed ID: 12433047
[TBL] [Abstract][Full Text] [Related]
35. A novel [99mTc[triple bond]N]2+ complex of metronidazole xanthate as a potential agent for targeting hypoxia.
Mallia MB; Mathur A; Subramanian S; Banerjee S; Sarma HD; Venkatesh M
Bioorg Med Chem Lett; 2005 Jul; 15(14):3398-401. PubMed ID: 16044527
[TBL] [Abstract][Full Text] [Related]
36. Preclinical assessment of hypoxic marker specificity and sensitivity.
Iyer RV; Engelhardt EL; Stobbe CC; Schneider RF; Chapman JD
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):741-5. PubMed ID: 9845088
[TBL] [Abstract][Full Text] [Related]
37. The synthesis and in vitro evaluation of a 99mtechnetium-nitroimidazole complex based on a bis(amine-phenol) ligand: comparison to BMS-181321.
Ramalingam K; Raju N; Nanjappan P; Linder KE; Pirro J; Zeng W; Rumsey W; Nowotnik DP; Nunn AD
J Med Chem; 1994 Nov; 37(24):4155-63. PubMed ID: 7990115
[TBL] [Abstract][Full Text] [Related]
38. Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: effect of lipophilicity.
Zhang X; Su ZF; Ballinger JR; Rauth AM; Pollak A; Thornback JR
Bioconjug Chem; 2000; 11(3):401-7. PubMed ID: 10821657
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of technetium-99m-labeled bioreductive pharmacophores conjugated with amino acids and peptides for tumor imaging.
Baishya R; Nayak DK; Karmakar S; Chattopadhyay S; Sachdeva SS; Sarkar BR; Ganguly S; Debnath MC
Chem Biol Drug Des; 2015 Apr; 85(4):504-17. PubMed ID: 25243793
[TBL] [Abstract][Full Text] [Related]
40. Tumor imaging with technetium-99m-DTPA encapsulated in RES-avoiding liposomes.
Oku N; Namba Y; Takeda A; Okada S
Nucl Med Biol; 1993 May; 20(4):407-12. PubMed ID: 8504283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
